These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2841709)

  • 1. The use of opiate antagonists in treating bulimia: a study of low-dose versus high-dose naltrexone.
    Jonas JM; Gold MS
    Psychiatry Res; 1988 May; 24(2):195-9. PubMed ID: 2841709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naltrexone treatment of bulimia: clinical and theoretical findings linking eating disorders and substance abuse.
    Jonas JM; Gold MS
    Adv Alcohol Subst Abuse; 1987; 7(1):29-37. PubMed ID: 2831700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binge eating disorder: response to naltrexone.
    Marrazzi MA; Markham KM; Kinzie J; Luby ED
    Int J Obes Relat Metab Disord; 1995 Feb; 19(2):143-5. PubMed ID: 7735342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naltrexone Reduces Binge Eating and Purging in Adolescents in an Eating Disorder Program.
    Stancil SL; Adelman W; Dietz A; Abdel-Rahman S
    J Child Adolesc Psychopharmacol; 2019 Nov; 29(9):721-724. PubMed ID: 31313939
    [No Abstract]   [Full Text] [Related]  

  • 5. Naltrexone in organic bulimia: a preliminary report.
    Childs A
    Brain Inj; 1987; 1(1):49-55. PubMed ID: 3454671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the opiate antagonist, naltrexone, on binging antecedents and plasma beta-endorphin concentrations.
    Chatoor I; Herman BH; Hartzler J
    J Am Acad Child Adolesc Psychiatry; 1994 Jun; 33(5):748-52. PubMed ID: 8056738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa.
    Marrazzi MA; Bacon JP; Kinzie J; Luby ED
    Int Clin Psychopharmacol; 1995 Sep; 10(3):163-72. PubMed ID: 8675969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of antidepressant-resistant bulimia with naltrexone.
    Jonas JM; Gold MS
    Int J Psychiatry Med; 1986-1987; 16(4):305-9. PubMed ID: 3557806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose naltrexone and liver function safety.
    Marrazzi MA; Wroblewski JM; Kinzie J; Luby ED
    Am J Addict; 1997; 6(1):21-9. PubMed ID: 9097868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a tricyclic antidepressant and opiate antagonist on binge-eating behavior in normoweight bulimic and obese, binge-eating subjects.
    Alger SA; Schwalberg MD; Bigaouette JM; Michalek AV; Howard LJ
    Am J Clin Nutr; 1991 Apr; 53(4):865-71. PubMed ID: 2008865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A placebo-controlled, double-blind crossover study of naltrexone hydrochloride in outpatients with normal weight bulimia.
    Mitchell JE; Christenson G; Jennings J; Huber M; Thomas B; Pomeroy C; Morley J
    J Clin Psychopharmacol; 1989 Apr; 9(2):94-7. PubMed ID: 2656781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A detailed longitudinal analysis on the use of naltrexone in the treatment of bulimia.
    Marrazzi MA; Kinzie J; Luby ED
    Int Clin Psychopharmacol; 1995 Sep; 10(3):173-6. PubMed ID: 8675970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Opiate hypothesis in infantile autism? Therapeutic trials with naltrexone].
    Leboyer M; Bouvard MP; Launay JM; Recasens C; Plumet MH; Waller-Perotte D; Tabuteau F; Bondoux D; Dugas M
    Encephale; 1993; 19(2):95-102. PubMed ID: 8275903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial.
    Faris PL; Kim SW; Meller WH; Goodale RL; Oakman SA; Hofbauer RD; Marshall AM; Daughters RS; Banerjee-Stevens D; Eckert ED; Hartman BK
    Lancet; 2000 Mar; 355(9206):792-7. PubMed ID: 10711927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naltrexone modulates body and brain development in rats: a role for endogenous opioid systems in growth.
    Zagon IS; McLaughlin PJ
    Life Sci; 1984 Nov; 35(20):2057-64. PubMed ID: 6092812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latent class analysis of eating and impulsive behavioral symptoms in Taiwanese women with bulimia nervosa.
    Tseng MC; Hu FC
    J Psychosom Res; 2012 Jan; 72(1):65-72. PubMed ID: 22200525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial.
    Hudson JI; McElroy SL; Raymond NC; Crow S; Keck PE; Carter WP; Mitchell JE; Strakowski SM; Pope HG; Coleman BS; Jonas JM
    Am J Psychiatry; 1998 Dec; 155(12):1756-62. PubMed ID: 9842788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of naltrexone, a long-acting opiate antagonist.
    Crabtree BL
    Clin Pharm; 1984; 3(3):273-80. PubMed ID: 6329589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of nonpurging bulimia nervosa with desipramine: a double-blind, placebo-controlled study.
    McCann UD; Agras WS
    Am J Psychiatry; 1990 Nov; 147(11):1509-13. PubMed ID: 2221164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naltrexone effects on ethanol drinking acquisition and on established ethanol consumption in C57BL/6J mice.
    Phillips TJ; Wenger CD; Dorow JD
    Alcohol Clin Exp Res; 1997 Jun; 21(4):691-702. PubMed ID: 9194926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.